{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:56:01Z","timestamp":1784152561713,"version":"3.55.0"},"publisher-location":"Cham","reference-count":20,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031871665","type":"print"},{"value":"9783031871672","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/82_2024_281","type":"book-chapter","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:53:12Z","timestamp":1733482392000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Importance of Antibody Titer Determination to the Effective Use of Convalescent Plasma"],"prefix":"10.1007","author":[{"given":"Peter W.","family":"Marks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"issue":"11","key":"281_CR1","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-2600(19)30199-7","volume":"7","author":"JH Beigel","year":"2019","unstructured":"Beigel JH, Aga E, Elie-Turenne MC et al (2019) Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med 7(11):941\u2013950. https:\/\/doi.org\/10.1016\/S2213-2600(19)30199-7","journal-title":"Lancet Respir Med"},{"issue":"6","key":"281_CR2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/ajh.26531","volume":"97","author":"A Belov","year":"2022","unstructured":"Belov A, Huang Y, Villa CH et al (2022) Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol 97(6):770\u2013779. https:\/\/doi.org\/10.1002\/ajh.26531","journal-title":"Am J Hematol"},{"issue":"5","key":"281_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17476348.2023.2208349","volume":"17","author":"A Casadevall","year":"2023","unstructured":"Casadevall A, Joyner MJ, Pirofski LA et al (2023) Convalescent plasma therapy in COVID-19: unravelling the data using the principles of antibody therapy. Expert Rev Respir Med 17(5):381\u2013395. https:\/\/doi.org\/10.1080\/17476348.2023.2208349","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"281_CR4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/trf.17701","volume":"64","author":"M Franchini","year":"2024","unstructured":"Franchini M, Cruciani M, Casadevall A et al (2024) Safety of COVID-19 convalescent plasma: a definitive systematic review and meta-analysis of randomized controlled trials. Transfusion 64(2):388\u2013399. https:\/\/doi.org\/10.1111\/trf.17701","journal-title":"Transfusion"},{"issue":"4","key":"281_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/cid\/ciq106","volume":"52","author":"IF Hung","year":"2011","unstructured":"Hung IF, To KK, Lee CK et al (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52(4):447\u2013456. https:\/\/doi.org\/10.1093\/cid\/ciq106","journal-title":"Clin Infect Dis"},{"issue":"9","key":"281_CR6","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1172\/JCI140200","volume":"130","author":"MJ Joyner","year":"2020","unstructured":"Joyner MJ, Wright RS, Fairweather D et al (2020) Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest 130(9):4791\u20134797. https:\/\/doi.org\/10.1172\/JCI140200","journal-title":"J Clin Invest"},{"issue":"8","key":"281_CR7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/trf.15921","volume":"60","author":"L Li","year":"2020","unstructured":"Li L, Yang R, Wang J et al (2020) Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China. Transfusion 60(8):1773\u20131777. https:\/\/doi.org\/10.1111\/trf.15921","journal-title":"Transfusion"},{"issue":"8","key":"281_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","volume":"145","author":"TC Luke","year":"2006","unstructured":"Luke TC, Kilbane EM, Jackson JL, Hoffman SL (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145(8):599\u2013609. https:\/\/doi.org\/10.7326\/0003-4819-145-8-200610170-00139","journal-title":"Ann Intern Med"},{"key":"281_CR9","doi-asserted-by":"publisher","unstructured":"Maiztegui JI, Fernandez NJ, de Damilano AJ (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2(8154):1216\u20131217. https:\/\/doi.org\/10.1016\/s0140-6736(79)92335-3","DOI":"10.1016\/s0140-6736(79)92335-3"},{"issue":"12","key":"281_CR10","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1093\/jac\/dkw338","volume":"71","author":"Y Mo","year":"2016","unstructured":"Mo Y, Fisher D (2016) A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother 71(12):3340\u20133350. https:\/\/doi.org\/10.1093\/jac\/dkw338","journal-title":"J Antimicrob Chemother"},{"key":"281_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/978-1-0716-2111-0_18","volume":"2452","author":"SN Neerukonda","year":"2022","unstructured":"Neerukonda SN, Vassell R, Weiss CD, Wang W (2022) Measuring neutralizing antibodies to SARS-CoV-2 using lentiviral spike-pseudoviruses. Methods Mol Biol 2452:305\u2013314. https:\/\/doi.org\/10.1007\/978-1-0716-2111-0_18","journal-title":"Methods Mol Biol"},{"issue":"4","key":"281_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clinmicnews.2021.02.001","volume":"43","author":"JG Ripoll","year":"2021","unstructured":"Ripoll JG, van Helmond N, Senefeld JW et al (2021) Convalescent plasma for infectious diseases: historical framework and use in COVID-19. Clin Microbiol Newsl 43(4):23\u201332. https:\/\/doi.org\/10.1016\/j.clinmicnews.2021.02.001","journal-title":"Clin Microbiol Newsl"},{"key":"281_CR13","unstructured":"Ruggiero HA, P\u00e9rez Isquierdo F et al. (1986) Traitement de la fi\u00e8vre h\u00e9morragique argentine par le plasma de convalescent. 4,433 cas [Treatment of Argentine hemorrhagic fever with convalescent\u2019s plasma. 4433 cases]. Presse Med 15(45):2239\u20132242. French. PMID: 2949253"},{"issue":"12","key":"281_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003872","volume":"18","author":"JW Senefeld","year":"2021","unstructured":"Senefeld JW, Johnson PW, Kunze KL et al (2021) Access to and safety of COVID-19 convalescent plasma in the United States expanded access program: a national registry study. PLoS Med 18(12):e1003872. https:\/\/doi.org\/10.1371\/journal.pmed.1003872","journal-title":"PLoS Med"},{"issue":"4","key":"281_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/hematolrep14040052","volume":"14","author":"S Shibeeb","year":"2022","unstructured":"Shibeeb S, Ajaj I, Al-Jighefee H, Abdallah AM (2022) Effectiveness of convalescent plasma therapy in COVID-19 patients with hematological malignancies: a systematic review. Hematol Rep 14(4):377\u2013388. https:\/\/doi.org\/10.3390\/hematolrep14040052","journal-title":"Hematol Rep"},{"issue":"1","key":"281_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1511812","volume":"374","author":"J van Griensven","year":"2016","unstructured":"van Griensven J, Edwards T, de Lamballerie X et al (2016a) Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374(1):33\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1511812","journal-title":"N Engl J Med"},{"key":"281_CR17","doi-asserted-by":"publisher","unstructured":"van Griensven J, Edwards T, Baize S (2016b) Ebola-Tx consortium. Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies. N Engl J Med 375(23):2307\u20132309. https:\/\/doi.org\/10.1056\/NEJMc1609116","DOI":"10.1056\/NEJMc1609116"},{"issue":"1","key":"281_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s13054-020-03189-7","volume":"24","author":"Z Xu","year":"2020","unstructured":"Xu Z, Zhou J, Huang Y et al (2020) Efficacy of convalescent plasma for the treatment of severe influenza. Crit Care 24(1):469. https:\/\/doi.org\/10.1186\/s13054-020-03189-7","journal-title":"Crit Care"},{"issue":"10","key":"281_CR19","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/jmv.25882","volume":"92","author":"M Ye","year":"2020","unstructured":"Ye M, Fu D, Ren Y et al (2020) Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 92(10):1890\u20131901. https:\/\/doi.org\/10.1002\/jmv.25882","journal-title":"J Med Virol."},{"key":"281_CR20","doi-asserted-by":"publisher","unstructured":"Zhang S, Ma P, Orzechowski M et al (2023) High-throughput neutralization and serology assays reveal correlated but highly variable humoral immune responses in a large population of individuals infected with SARS-CoV-2 in the US between March and August 2020. 14(2):e0352322. https:\/\/doi.org\/10.1128\/mbio.03523-22","DOI":"10.1128\/mbio.03523-22"}],"container-title":["Current Topics in Microbiology and Immunology","Convalescent Plasma and Other Antibody Therapies for Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2024_281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:53:50Z","timestamp":1784109230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2024_281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031871665","9783031871672"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/82_2024_281","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"7 December 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The author has no conflicts of interest to declare, and no funding was obtained for this work. This chapter reflects the views of the author and should not be construed to represent FDA\u2019s views or policies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}